“Our success with RayStation® continues and during the year, the order intake
for RayStation® doubled to SEK 317 M (159). Overall, revenues rose 39 percent
and we are presenting the best full-year results ever, despite continued
expansion of our global market organization. We are also seeing a huge interest
in RayCare®, for which we have now signed a long-term collaboration agreement
with the University of California, San Francisco. RayCare® is an innovative
oncology information system and represents a completely new product area for
RaySearch. Based on the company’s increased profit, the Board of Directors
proposes that dividend payments be resumed,” says Johan Löf, President and CEO
of RaySearch.
TWELVE MONTHS (JANUARY-DECEMBER, 2015)
· Net sales SEK 397.6 M (285.2), of which RayStation® SEK 300.4 M (190.2)
· Profit after tax SEK 70.2 M (59.8), and earnings per share SEK 2.05 (1.75)
· Operating profit SEK 95.3 M (79.4)
· Cash flow SEK 3.6 M (16.8)
· Order intake excluding service agreements SEK 385.2 M (229.8), of which
RayStation® SEK 316.9 M (158.9)
· Based on the company’s increased profitability, the Board of Directors
proposes that dividend payments be resumed with a full-year 2015 dividend of SEK
0.25 per share
FOURTH QUARTER (OCTOBER-DECEMBER, 2015)
· Net sales SEK 132.0 M (107.8), of which RayStation® SEK 109.4 M (84.9)
· Profit after tax SEK 33.3 M (40.7), and earnings per share SEK 0.97 (1.19)
· Operating profit SEK 44.3 M (52.8)
· Cash flow SEK 12.4 M (30.7)
· Cash SEK 59,7 M (56,1) at the end of the period
· Order intake excluding service agreements SEK 117.9 M (85.4), of which
RayStation® SEK 102.9 M (70.4)
· At the end of the period, RayStation® order backlog totaled SEK 60.5 M
(31.5)
SIGNIFICANT EVENTS DURING THE FOURTH QUARTER
· In November 2015, Anders Liander, CTO, left the company to pursue his own
interests
· In November 2015, 1,061,577 Class A shares were converted to Class B shares
at the request of a shareholder. The total number of votes in RaySearch
thereafter amounted to 126,648,099. The total number of registered shares in
RaySearch amounts to 34,282,773, of which 10,262,814 are Class A shares and
24,019,959 are Class B shares
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
· RaySearch has released RayStation® 5 with support for carbon ion treatment
planning, which represents the most advanced form of radiation therapy, as well
as tools and functionality that bring a new perspective to treatment planning
· RaySearch has signed a long-term collaboration agreement with the University
of California, San Francisco (UCSF) regarding the RayCare® oncology information
system, which is currently under development at RaySearch
· On January 4, 2016, RaySearch’s Class B share (RAY B) was transferred from
the Small Cap to the Mid Cap segment of Nasdaq Stockholm
FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, President and CEO
Tel: +46 8 510 530 00
johan.lof@raysearchlabs.com
The information in this interim report is such that RaySearch is required to
disclose publicly in accordance with the Swedish Securities and Clearing
Operations Act and/or the Swedish Financial Instruments Trading Act. The
information was submitted for publication on February 18, 2016 at 7:45 a.m.
ABOUT RAYSEARCH
RaySearch Laboratories AB (publ) is a medical technology company that develops
advanced software solutions for improved radiation therapy of cancer. RaySearch
markets the RayStation® treatment planning system to clinics all over the world.
In addition, RaySearch’s products are distributed through licensing agreements
with leading medical technology companies. RaySearch’s software is used by over
2,600 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin
-off from Karolinska Institute in Stockholm, and the company is listed in the
Mid Cap segment on Nasdaq Stockholm. More information about RaySearch is
available at www.raysearchlabs.com.
